Evidence map›Paper›PMID 26134705›Full record

ArticlePituitary2015

AVP-NPII gene mutations and clinical characteristics of the patients with autosomal dominant familial central diabetes insipidus.

Doga Turkkahraman, Emel Saglar, Tugce Karaduman, Hatice Mergen

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Central diabetes insipidus.Nagoya journal of medical science · 2016
    Review
  5. Article
  6. Diagnosis and Treatment of Hypopituitarism.Endocrinology and metabolism (Seoul, Korea) · 2015
    Review
  7. Article
  8. Article
  9. Diabetes insipidus: The other diabetes.Indian journal of endocrinology and metabolism
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Doga TurkkahramanDepartment of Pediatric Endocrinology, Antalya Education and Research Hospital, Antalya, Turkey. drdoga@hotmail.com.
Emel SaglarDepartment of Biology, Faculty of Science, Hacettepe University, Beytepe, Ankara, Turkey.
Tugce KaradumanDepartment of Biology, Faculty of Science, Hacettepe University, Beytepe, Ankara, Turkey.
Hatice MergenDepartment of Biology, Faculty of Science, Hacettepe University, Beytepe, Ankara, Turkey.
Hacettepe University · TRAntalya Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial central diabetes insipidus (DI), usually an autosomal dominant disorder, is caused by mutations in arginine vasopressin-neurophysin II (AVP-NPII) gene that leads to aberrant preprohormone processing and gradual destruction of AVP-secreting cells.

objectiveTo determine clinical and molecular characteristics of patients with familial central DI from two different Turkish families. MATERIALS AND

methodsThe diagnosis of central DI was established by 24-h urine collection, water deprivation test, and desmopressin challenge. To confirm the diagnosis of familial central DI, the entire coding region of AVP-NPII gene was amplified and sequenced. A total of eight affected patients and three unaffected healthy relatives from two families were studied.

resultsGenetic analysis revealed a previously reported heterozygous mutation (p.C98X) in family A, and a heterozygous novel mutation (p.G45C) in family B, both detected in exon 2 of AVP-NPII gene. When we compared the clinical characteristics of the two families, it was noticed that as the age of onset of symptoms in family A ranges between 4 and 7 years, it was <1 year in family B. Additionally, pituitary bright spot was present in the affected siblings, but absent in their affected parents.

conclusionFamilial central DI is a progressive disease, and age of onset of symptoms can differ depending on the mutation. Bright spot on pituitary MRI might be present at onset, but become invisible over time. Genetic testing and appropriate counseling should be given in familial cases of central DI to ensure adequate treatment, and to avoid chronic water deprivation that might result in growth retardation in childhood.

Indexed as

AdultChildDiabetes Insipidus, NeurogenicFemaleHumansMaleMutationNeurophysinsProtein PrecursorsVasopressinsAVP protein, humanNeurophysinsProtein PrecursorsVasopressinsAVP-NPII geneFamilial central diabetes insipidusMutation

Identifiers

PMID26134705
OpenAlexW797220708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.